Oncorus Inc. (NASDAQ:ONCR) shares traded -3.16% lower at $0.30 on Wall Street last session.
In accordance with the data, 4 analysts cover Oncorus Inc. (NASDAQ:ONCR). The consensus rating among analysts is ‘Overweight’. ONCR stock price is now -33.37% away from the 50-day moving average and -71.60% away from the 200-day moving average. The market capitalization of the company currently stands at $7.84M.
It has been rated a hold by 2 analysts and a buy by 2.
With the price target of $35, Maxim Group recently initiated with Buy rating for Oncorus Inc. (NASDAQ: ONCR). On October 27, 2020, Piper Sandler recently initiated its ‘Overweight’ rating on the stock quoting a target price of $40, while ‘Jefferies’ rates the stock as ‘Buy’.
In other news, Flynn James E, Possible Member of 10% Group sold 138,872 shares of the company’s stock on Dec 30. The stock was sold for $37,495 at an average price of $0.27. Upon completion of the transaction, the Possible Member of 10% Group now directly owns 284,697 shares in the company, valued at $85409.1. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 29, Possible Member of 10% Group Flynn James E sold 141,753 shares of the business’s stock. A total of $36,856 was realized by selling the stock at an average price of $0.26. This leaves the insider owning 299,917 shares of the company worth $89975.1. Insiders disposed of 87,170 shares of company stock worth roughly $26151.0 over the past 1 year. A total of 8.93% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ONCR stock. A new stake in Oncorus Inc. shares was purchased by AMALGAMATED FINANCIAL CORP. during the first quarter worth $1,000. In total, there are 73 active investors with 65.20% ownership of the company’s stock.
Oncorus Inc. (NASDAQ: ONCR) opened at $0.3100 on Thursday. During the past 12 months, Oncorus Inc. has had a low of $0.23 and a high of $4.68. As of last week, the company has a debt-to-equity ratio of 0.24, a current ratio of 5.00, and a quick ratio of 5.00. The fifty day moving average price for ONCR is $0.4505 and a two-hundred day moving average price translates $1.0570 for the stock.
The latest earnings results from Oncorus Inc. (NASDAQ: ONCR) was released for Jun, 2022.
Oncorus Inc.(ONCR) Company Profile
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company’s lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck’s cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.